The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-10-27

AUTHORS

Jason Gordon, Phil McEwan, Michael Hurst, Jorge Puelles

ABSTRACT

INTRODUCTION: ENDURE (ClinicalTrials.gov identifier, NCT00856284), a multicenter, double-blind, active-controlled study of 2639 patients with uncontrolled type 2 diabetes mellitus (T2DM), found that metformin in combination with alogliptin (12.5 and 25 mg doses), when compared to standard add-on therapy (sulfonylurea, SU), exerted sustained antihyperglycemic effects over 2 years. This economic analysis of ENDURE aimed to quantify the relationship between increased glycemic durability and cost-effectiveness of alogliptin in the UK clinical setting, and communicate its sustained glycemic benefit in economic terms. METHODS: Using baseline characteristics and treatment effects from the ENDURE trial population, between-group cost-effectiveness analyses compared the combined use of metformin and alogliptin (MET + ALO12.5/25) in patients with inadequately controlled T2DM, as an alternative to metformin and SU (MET + SU). In scenario analyses, an intragroup cost-effectiveness analysis compared MET + ALO12.5/25 with MET + SU; a between-group cost-effectiveness analysis also compared MET + ALO12.5/25 versus MET + SU within a subpopulation of patients who achieved HbA1c control (<7.5%) at 2 years on study drug. RESULTS: Compared with baseline profiles of patients, combination therapies with alogliptin or SU were associated with improvements in length and quality of life and were cost-effective at established norms. Despite increased drug acquisition costs, alogliptin at 12.5 mg and 25 mg doses resulted in greater predicted lifetime quality-adjusted life year (QALY) gains with associated incremental cost-effectiveness ratios (ICERs) of £10,959/QALY and £7217/QALY compared to SU, respectively. CONCLUSION: The ENDURE trial and the present cost-effectiveness analysis found that the glycemic durability of alogliptin therapy was associated with improved long-term patient outcomes, QALY gains, and ICERs that were cost-effective when evaluated against standard threshold values. Alogliptin therefore represents a cost-effective treatment alternative to SU as add-on therapy to metformin in patients with poorly managed T2DM. FUNDING: Takeda Development Centre Europe Ltd. More... »

PAGES

825-845

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-016-0206-7

DOI

http://dx.doi.org/10.1007/s13300-016-0206-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1035136865

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27787778


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Applied Economics", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Public Health, University of Adelaide, Adelaide, Australia", 
          "id": "http://www.grid.ac/institutes/grid.1010.0", 
          "name": [
            "Health Economics and Outcomes Research Ltd, Cardiff, UK", 
            "School of Medicine, University of Nottingham, Nottingham, UK", 
            "Department of Public Health, University of Adelaide, Adelaide, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gordon", 
        "givenName": "Jason", 
        "id": "sg:person.01171526060.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171526060.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Swansea Centre for Health Economics, Swansea University, Swansea, UK", 
          "id": "http://www.grid.ac/institutes/grid.4827.9", 
          "name": [
            "Health Economics and Outcomes Research Ltd, Cardiff, UK", 
            "Swansea Centre for Health Economics, Swansea University, Swansea, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McEwan", 
        "givenName": "Phil", 
        "id": "sg:person.01346767345.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346767345.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Health Economics and Outcomes Research Ltd, Cardiff, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Health Economics and Outcomes Research Ltd, Cardiff, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hurst", 
        "givenName": "Michael", 
        "id": "sg:person.013133534541.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013133534541.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Global Outcomes Research, Takeda Development Centre Europe Ltd, London, UK", 
          "id": "http://www.grid.ac/institutes/grid.451362.7", 
          "name": [
            "Global Outcomes Research, Takeda Development Centre Europe Ltd, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Puelles", 
        "givenName": "Jorge", 
        "id": "sg:person.01165575563.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165575563.09"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.2165/11597060-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033801058", 
          "https://doi.org/10.2165/11597060-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40273-015-0266-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032283136", 
          "https://doi.org/10.1007/s40273-015-0266-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/2191-1991-3-11", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049529295", 
          "https://doi.org/10.1186/2191-1991-3-11"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/2191-1991-3-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030032597", 
          "https://doi.org/10.1186/2191-1991-3-1"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-10-27", 
    "datePublishedReg": "2016-10-27", 
    "description": "INTRODUCTION: ENDURE (ClinicalTrials.gov identifier, NCT00856284), a multicenter, double-blind, active-controlled study of 2639 patients with uncontrolled type 2 diabetes mellitus (T2DM), found that metformin in combination with alogliptin (12.5 and 25\u00a0mg doses), when compared to standard add-on therapy (sulfonylurea, SU), exerted sustained antihyperglycemic effects over 2\u00a0years. This economic analysis of ENDURE aimed to quantify the relationship between increased glycemic durability and cost-effectiveness of alogliptin in the UK clinical setting, and communicate its sustained glycemic benefit in economic terms.\nMETHODS: Using baseline characteristics and treatment effects from the ENDURE trial population, between-group cost-effectiveness analyses compared the combined use of metformin and alogliptin (MET\u00a0+\u00a0ALO12.5/25) in patients with inadequately controlled T2DM, as an alternative to metformin and SU (MET\u00a0+\u00a0SU). In scenario analyses, an intragroup cost-effectiveness analysis compared MET\u00a0+\u00a0ALO12.5/25 with MET\u00a0+\u00a0SU; a between-group cost-effectiveness analysis also compared MET\u00a0+\u00a0ALO12.5/25 versus MET\u00a0+\u00a0SU within a subpopulation of patients who achieved HbA1c control (<7.5%) at 2\u00a0years on study drug.\nRESULTS: Compared with baseline profiles of patients, combination therapies with alogliptin or SU were associated with improvements in length and quality of life and were cost-effective at established norms. Despite increased drug acquisition costs, alogliptin at 12.5\u00a0mg and 25\u00a0mg doses resulted in greater predicted lifetime quality-adjusted life year (QALY) gains with associated incremental cost-effectiveness ratios (ICERs) of \u00a310,959/QALY and \u00a37217/QALY compared to SU, respectively.\nCONCLUSION: The ENDURE trial and the present cost-effectiveness analysis found that the glycemic durability of alogliptin therapy was associated with improved long-term patient outcomes, QALY gains, and ICERs that were cost-effective when evaluated against standard threshold values. Alogliptin therefore represents a cost-effective treatment alternative to SU as add-on therapy to metformin in patients with poorly managed T2DM.\nFUNDING: Takeda Development Centre Europe Ltd.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-016-0206-7", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "7"
      }
    ], 
    "keywords": [
      "quality-adjusted life years", 
      "incremental cost-effectiveness ratio", 
      "cost-effectiveness analysis", 
      "glycemic durability", 
      "uncontrolled type 2 diabetes mellitus", 
      "type 2 diabetes mellitus", 
      "long-term patient outcomes", 
      "improved long-term patient outcomes", 
      "use of metformin", 
      "Uncontrolled Type 2", 
      "lifetime quality-adjusted life years", 
      "subpopulation of patients", 
      "drug acquisition costs", 
      "active-controlled study", 
      "cost-effective treatment alternative", 
      "cost-effectiveness ratio", 
      "quality of life", 
      "alogliptin therapy", 
      "study drug", 
      "baseline characteristics", 
      "diabetes mellitus", 
      "trial population", 
      "combination therapy", 
      "antihyperglycemic effect", 
      "patient outcomes", 
      "glycemic benefits", 
      "patients", 
      "metformin", 
      "life years", 
      "type 2", 
      "QALY gain", 
      "alogliptin", 
      "therapy", 
      "treatment alternatives", 
      "present cost-effectiveness analysis", 
      "mellitus", 
      "T2DM", 
      "MetS", 
      "treatment effects", 
      "standard threshold value", 
      "acquisition costs", 
      "years", 
      "baseline profile", 
      "multicenter", 
      "sulfonylureas", 
      "doses", 
      "economic analysis", 
      "trials", 
      "economic terms", 
      "drugs", 
      "outcomes", 
      "subpopulations", 
      "scenario analysis", 
      "effect", 
      "add", 
      "population", 
      "analysis", 
      "control", 
      "study", 
      "life", 
      "SU", 
      "benefits", 
      "alternative", 
      "improvement", 
      "established norms", 
      "profile", 
      "use", 
      "UK", 
      "combination", 
      "quality", 
      "relationship", 
      "cost", 
      "ratio", 
      "threshold value", 
      "gain", 
      "endures", 
      "length", 
      "characteristics", 
      "values", 
      "durability", 
      "norms", 
      "terms", 
      "AlO", 
      "Ltd.", 
      "sustained antihyperglycemic effects", 
      "sustained glycemic benefit", 
      "ENDURE trial population", 
      "group cost-effectiveness analyses", 
      "intragroup cost-effectiveness analysis", 
      "ENDURE trial", 
      "Takeda Development Centre Europe Ltd.", 
      "Development Centre Europe Ltd.", 
      "Centre Europe Ltd.", 
      "Europe Ltd.", 
      "Alogliptin Versus Sulfonylurea", 
      "Versus Sulfonylurea"
    ], 
    "name": "The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus", 
    "pagination": "825-845", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1035136865"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-016-0206-7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27787778"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-016-0206-7", 
      "https://app.dimensions.ai/details/publication/pub.1035136865"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_694.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-016-0206-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-016-0206-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-016-0206-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-016-0206-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-016-0206-7'


 

This table displays all metadata directly associated to this object as RDF triples.

207 TRIPLES      22 PREDICATES      126 URIs      114 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-016-0206-7 schema:about anzsrc-for:14
2 anzsrc-for:1402
3 schema:author Ne4e8ce426f4841b3a747f08d6d859499
4 schema:citation sg:pub.10.1007/s40273-015-0266-y
5 sg:pub.10.1186/2191-1991-3-1
6 sg:pub.10.1186/2191-1991-3-11
7 sg:pub.10.2165/11597060-000000000-00000
8 schema:datePublished 2016-10-27
9 schema:datePublishedReg 2016-10-27
10 schema:description INTRODUCTION: ENDURE (ClinicalTrials.gov identifier, NCT00856284), a multicenter, double-blind, active-controlled study of 2639 patients with uncontrolled type 2 diabetes mellitus (T2DM), found that metformin in combination with alogliptin (12.5 and 25 mg doses), when compared to standard add-on therapy (sulfonylurea, SU), exerted sustained antihyperglycemic effects over 2 years. This economic analysis of ENDURE aimed to quantify the relationship between increased glycemic durability and cost-effectiveness of alogliptin in the UK clinical setting, and communicate its sustained glycemic benefit in economic terms. METHODS: Using baseline characteristics and treatment effects from the ENDURE trial population, between-group cost-effectiveness analyses compared the combined use of metformin and alogliptin (MET + ALO<sub>12.5/25</sub>) in patients with inadequately controlled T2DM, as an alternative to metformin and SU (MET + SU). In scenario analyses, an intragroup cost-effectiveness analysis compared MET + ALO<sub>12.5/25</sub> with MET + SU; a between-group cost-effectiveness analysis also compared MET + ALO<sub>12.5/25</sub> versus MET + SU within a subpopulation of patients who achieved HbA1c control (&lt;7.5%) at 2 years on study drug. RESULTS: Compared with baseline profiles of patients, combination therapies with alogliptin or SU were associated with improvements in length and quality of life and were cost-effective at established norms. Despite increased drug acquisition costs, alogliptin at 12.5 mg and 25 mg doses resulted in greater predicted lifetime quality-adjusted life year (QALY) gains with associated incremental cost-effectiveness ratios (ICERs) of £10,959/QALY and £7217/QALY compared to SU, respectively. CONCLUSION: The ENDURE trial and the present cost-effectiveness analysis found that the glycemic durability of alogliptin therapy was associated with improved long-term patient outcomes, QALY gains, and ICERs that were cost-effective when evaluated against standard threshold values. Alogliptin therefore represents a cost-effective treatment alternative to SU as add-on therapy to metformin in patients with poorly managed T2DM. FUNDING: Takeda Development Centre Europe Ltd.
11 schema:genre article
12 schema:inLanguage en
13 schema:isAccessibleForFree true
14 schema:isPartOf N94dd1aa3f88942c1b81baaa04dad5443
15 Nea3d0de4cae94d4d878267c7d15636d7
16 sg:journal.1044057
17 schema:keywords AlO
18 Alogliptin Versus Sulfonylurea
19 Centre Europe Ltd.
20 Development Centre Europe Ltd.
21 ENDURE trial
22 ENDURE trial population
23 Europe Ltd.
24 Ltd.
25 MetS
26 QALY gain
27 SU
28 T2DM
29 Takeda Development Centre Europe Ltd.
30 UK
31 Uncontrolled Type 2
32 Versus Sulfonylurea
33 acquisition costs
34 active-controlled study
35 add
36 alogliptin
37 alogliptin therapy
38 alternative
39 analysis
40 antihyperglycemic effect
41 baseline characteristics
42 baseline profile
43 benefits
44 characteristics
45 combination
46 combination therapy
47 control
48 cost
49 cost-effective treatment alternative
50 cost-effectiveness analysis
51 cost-effectiveness ratio
52 diabetes mellitus
53 doses
54 drug acquisition costs
55 drugs
56 durability
57 economic analysis
58 economic terms
59 effect
60 endures
61 established norms
62 gain
63 glycemic benefits
64 glycemic durability
65 group cost-effectiveness analyses
66 improved long-term patient outcomes
67 improvement
68 incremental cost-effectiveness ratio
69 intragroup cost-effectiveness analysis
70 length
71 life
72 life years
73 lifetime quality-adjusted life years
74 long-term patient outcomes
75 mellitus
76 metformin
77 multicenter
78 norms
79 outcomes
80 patient outcomes
81 patients
82 population
83 present cost-effectiveness analysis
84 profile
85 quality
86 quality of life
87 quality-adjusted life years
88 ratio
89 relationship
90 scenario analysis
91 standard threshold value
92 study
93 study drug
94 subpopulation of patients
95 subpopulations
96 sulfonylureas
97 sustained antihyperglycemic effects
98 sustained glycemic benefit
99 terms
100 therapy
101 threshold value
102 treatment alternatives
103 treatment effects
104 trial population
105 trials
106 type 2
107 type 2 diabetes mellitus
108 uncontrolled type 2 diabetes mellitus
109 use
110 use of metformin
111 values
112 years
113 schema:name The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
114 schema:pagination 825-845
115 schema:productId N0aa6620cc25d471eb537878ceea0e64d
116 N0c449faf98b84bd586b8d2ba0b39bfe6
117 Nf7c6980fd9884a929ea88c88a7b3771f
118 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035136865
119 https://doi.org/10.1007/s13300-016-0206-7
120 schema:sdDatePublished 2021-11-01T18:27
121 schema:sdLicense https://scigraph.springernature.com/explorer/license/
122 schema:sdPublisher N28e185653bde42f581551c304c91b962
123 schema:url https://doi.org/10.1007/s13300-016-0206-7
124 sgo:license sg:explorer/license/
125 sgo:sdDataset articles
126 rdf:type schema:ScholarlyArticle
127 N0aa6620cc25d471eb537878ceea0e64d schema:name pubmed_id
128 schema:value 27787778
129 rdf:type schema:PropertyValue
130 N0c449faf98b84bd586b8d2ba0b39bfe6 schema:name doi
131 schema:value 10.1007/s13300-016-0206-7
132 rdf:type schema:PropertyValue
133 N28e185653bde42f581551c304c91b962 schema:name Springer Nature - SN SciGraph project
134 rdf:type schema:Organization
135 N3c792e2e8444460ea9b54df506912b57 rdf:first sg:person.013133534541.78
136 rdf:rest Ne9a8769aca494efea447256e7faf7315
137 N737a93957321477b865079eff7392ea9 rdf:first sg:person.01346767345.38
138 rdf:rest N3c792e2e8444460ea9b54df506912b57
139 N94dd1aa3f88942c1b81baaa04dad5443 schema:volumeNumber 7
140 rdf:type schema:PublicationVolume
141 Ne4e8ce426f4841b3a747f08d6d859499 rdf:first sg:person.01171526060.18
142 rdf:rest N737a93957321477b865079eff7392ea9
143 Ne9a8769aca494efea447256e7faf7315 rdf:first sg:person.01165575563.09
144 rdf:rest rdf:nil
145 Nea3d0de4cae94d4d878267c7d15636d7 schema:issueNumber 4
146 rdf:type schema:PublicationIssue
147 Nf7c6980fd9884a929ea88c88a7b3771f schema:name dimensions_id
148 schema:value pub.1035136865
149 rdf:type schema:PropertyValue
150 anzsrc-for:14 schema:inDefinedTermSet anzsrc-for:
151 schema:name Economics
152 rdf:type schema:DefinedTerm
153 anzsrc-for:1402 schema:inDefinedTermSet anzsrc-for:
154 schema:name Applied Economics
155 rdf:type schema:DefinedTerm
156 sg:journal.1044057 schema:issn 1869-6953
157 1869-6961
158 schema:name Diabetes Therapy
159 schema:publisher Springer Nature
160 rdf:type schema:Periodical
161 sg:person.01165575563.09 schema:affiliation grid-institutes:grid.451362.7
162 schema:familyName Puelles
163 schema:givenName Jorge
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165575563.09
165 rdf:type schema:Person
166 sg:person.01171526060.18 schema:affiliation grid-institutes:grid.1010.0
167 schema:familyName Gordon
168 schema:givenName Jason
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171526060.18
170 rdf:type schema:Person
171 sg:person.013133534541.78 schema:affiliation grid-institutes:None
172 schema:familyName Hurst
173 schema:givenName Michael
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013133534541.78
175 rdf:type schema:Person
176 sg:person.01346767345.38 schema:affiliation grid-institutes:grid.4827.9
177 schema:familyName McEwan
178 schema:givenName Phil
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346767345.38
180 rdf:type schema:Person
181 sg:pub.10.1007/s40273-015-0266-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1032283136
182 https://doi.org/10.1007/s40273-015-0266-y
183 rdf:type schema:CreativeWork
184 sg:pub.10.1186/2191-1991-3-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030032597
185 https://doi.org/10.1186/2191-1991-3-1
186 rdf:type schema:CreativeWork
187 sg:pub.10.1186/2191-1991-3-11 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049529295
188 https://doi.org/10.1186/2191-1991-3-11
189 rdf:type schema:CreativeWork
190 sg:pub.10.2165/11597060-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033801058
191 https://doi.org/10.2165/11597060-000000000-00000
192 rdf:type schema:CreativeWork
193 grid-institutes:None schema:alternateName Health Economics and Outcomes Research Ltd, Cardiff, UK
194 schema:name Health Economics and Outcomes Research Ltd, Cardiff, UK
195 rdf:type schema:Organization
196 grid-institutes:grid.1010.0 schema:alternateName Department of Public Health, University of Adelaide, Adelaide, Australia
197 schema:name Department of Public Health, University of Adelaide, Adelaide, Australia
198 Health Economics and Outcomes Research Ltd, Cardiff, UK
199 School of Medicine, University of Nottingham, Nottingham, UK
200 rdf:type schema:Organization
201 grid-institutes:grid.451362.7 schema:alternateName Global Outcomes Research, Takeda Development Centre Europe Ltd, London, UK
202 schema:name Global Outcomes Research, Takeda Development Centre Europe Ltd, London, UK
203 rdf:type schema:Organization
204 grid-institutes:grid.4827.9 schema:alternateName Swansea Centre for Health Economics, Swansea University, Swansea, UK
205 schema:name Health Economics and Outcomes Research Ltd, Cardiff, UK
206 Swansea Centre for Health Economics, Swansea University, Swansea, UK
207 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...